Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03866382
Recruitment Status : Recruiting
First Posted : March 7, 2019
Last Update Posted : October 18, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Condition or disease Intervention/treatment Phase
Bladder Adenocarcinoma Bladder Mixed Adenocarcinoma Bladder Small Cell Carcinoma Bladder Squamous Cell Carcinoma Chromophobe Renal Cell Carcinoma Infiltrating Bladder Lymphoepithelioma-Like Carcinoma Infiltrating Bladder Urothelial Carcinoma Infiltrating Bladder Urothelial Carcinoma With Giant Cells Infiltrating Bladder Urothelial Carcinoma, Nested Variant Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant Kidney Medullary Carcinoma Large Cell Neuroendocrine Carcinoma Metastatic Bladder Carcinoma Metastatic Bladder Large Cell Neuroendocrine Carcinoma Metastatic Bladder Small Cell Carcinoma Metastatic Bladder Squamous Cell Carcinoma Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant Metastatic Kidney Medullary Carcinoma Metastatic Malignant Genitourinary System Neoplasm Metastatic Penile Carcinoma Metastatic Prostate Small Cell Carcinoma Metastatic Sarcomatoid Renal Cell Carcinoma Papillary Renal Cell Carcinoma Sarcomatoid Renal Cell Carcinoma Stage IV Bladder Cancer AJCC v8 Stage IV Penile Cancer AJCC v8 Stage IV Prostate Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Stage IVA Bladder Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Bladder Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8 Testicular Leydig Cell Tumor Testicular Sertoli Cell Tumor Drug: Cabozantinib Drug: Cabozantinib S-malate Biological: Ipilimumab Biological: Nivolumab Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of cabozantinib s-malate (cabozantinib) combined with nivolumab and ipilimumab in the first or second-line (and beyond) setting for patients within each of the rare genitourinary (GU) variant histology group of interest, as measured by objective response rate (ORR).

SECONDARY OBJECTIVES:

I. To estimate the progression-free survival (PFS) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

II. To estimate the overall survival (OS) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

III. To estimate the clinical benefit rate (defined as complete response [CR] or partial response [PR] or stable disease [SD]) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

IV. To assess the safety of treating patients with rare variant histologies with cabozantinib combined with nivolumab and ipilimumab.

V. To support tissue banking and collection of clinical follow-up data for GU tract rare histological variants.

EXPLORATORY OBJECTIVES:

I. To assess effects of treatment in patients with bone-only disease by bone scan.

OUTLINE:

Patients receive cabozantinib orally (PO) once daily (QD) on days 1-21 of cycles 1-4 and on days 1-28 of subsequent cycles. Patients also receive nivolumab intravenously (IV) over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Patients then receive nivolumab IV over 30 minutes on day 1 of subsequent cycles. Treatment repeats every 21 days for cycles 1-4 and every 28 days for subsequent cycles for 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 2 months for 5 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 186 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Actual Study Start Date : April 12, 2019
Estimated Primary Completion Date : February 28, 2023
Estimated Study Completion Date : February 28, 2023


Arm Intervention/treatment
Experimental: Treatment (cabozantinib, nivolumab, ipilimumab)
Patients receive cabozantinib PO QD on days 1-21 of cycles 1-4 and on days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Patients then receive nivolumab IV over 30 minutes on day 1 of subsequent cycles. Treatment repeats every 21 days for cycles 1-4 and every 28 days for subsequent cycles for 2 years in the absence of disease progression or unacceptable toxicity.
Drug: Cabozantinib
Given PO

Drug: Cabozantinib S-malate
Given PO
Other Names:
  • BMS-907351
  • Cabometyx
  • Cometriq
  • XL-184
  • XL184

Biological: Ipilimumab
Given IV
Other Names:
  • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
  • Yervoy

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo




Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Up to 5 years ]
    An objective response is defined as a confirmed complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Will be estimated by the number of confirmed objective responses divided by the total number of evaluable patients. Confidence intervals for the true ORR will be calculated.


Secondary Outcome Measures :
  1. Duration of response [ Time Frame: From time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 5 years ]
    Defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented.

  2. Progression-free survival (PFS) [ Time Frame: From start of treatment to time of progression or death, whichever occurs first, assessed up to 5 years ]
    The median its 95% confidence interval will be determined and will be summarized using the Kaplan-Meier estimator.

  3. Overall survival [ Time Frame: Up to 5 years ]
    The median its 95% confidence interval will be determined and will be summarized using the Kaplan-Meier estimator.

  4. Clinical benefit rate (CBR) [ Time Frame: Up to 5 years ]
    A confirmed clinical benefit is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart or a confirmed stable disease at two consecutive tumor assessments at least 3 months apart. The CBR will be estimated by the number of patients with confirmed clinical benefit divided by the total number of evaluable patients. Confidence intervals for the true CBR will be calculated using exact binomial confidence intervals.

  5. Incidence of adverse events (AE) [ Time Frame: Up to 5 years ]
    Will be assessed using Common Terminology Criteria for Adverse Events version 5.0. The maximum of a particular AE will be determined for each patient. Tables will summarize the number and relative frequency of patients observing an AE as well as the number and relative frequency of patients experiencing any AE of grade 3 or greater.


Other Outcome Measures:
  1. Effects of treatment in patients with bone-only disease [ Time Frame: Up to 5 years ]
    The bone-only tumor patients will be evaluated in an exploratory fashion (if no RECIST measurements are available). A maximum of 15 patients with bone-only disease will be enrolled and evaluated using PFS for a descriptive analysis of the effect of treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least:

    • One measurable site of disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
    • One bone lesion on bone scan (tec99 or sodium fluoride [NaF] positron emission tomography [PET]/computed tomography [CT], CT, or magnetic resonance imaging [MRI]) for the bone-only cohort
    • Histologically confirmed diagnosis of metastatic: small cell carcinoma of the bladder; adenocarcinoma of the bladder; squamous cell carcinoma of the bladder; plasmacytoid urothelial carcinoma; any penile cancer; sarcomatoid renal cell carcinoma; sarcomatoid urothelial carcinoma; renal medullary carcinoma or other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to micropapillary, giant cell, lipid-rich, clear cell and nested variants, large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer, testicular Sertoli or Leydig cell tumors, and papillary and chromophobe renal cell carcinoma (RCC)
    • Hematoxylin and eosin (H&E) slides from diagnostic tumor tissue for retrospective central pathology review
  • Patients may have received any number of prior anti-cancer treatments or be treatment naive (with the exception of patients with small cell carcinoma of the bladder, whom should have received a platinum-based combination regimen either as neoadjuvant, adjuvant or first-line treatment)
  • Patients must be able to swallow oral formulation of the tablets
  • Karnofsky performance status >= 70%
  • Absolute neutrophil count (ANC) >= 1,200/mcL
  • Platelet count >= 75,000/mcL
  • Total bilirubin =< 1.5 x upper limit of normal (ULN). For subjects with known Gilbert's disease or similar syndrome with slow conjugation of bilirubin, total bilirubin =< 3.0 mg/dL
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN) (or =< 5 x ULN for patients with liver metastases or Gilbert's disease)
  • Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance >= 40 mL/min/1.73 m^2 (calculated using the Chronic Kidney Disease Epidemiology [CKD-EPI] equation or Cockcroft-Gault formula) for patients with creatinine levels above institutional normal
  • Hemoglobin >= 9 g/dL (transfusion of packed red blood cells [PRBCs] allowed)
  • Serum albumin >= 2.8 g/dL
  • Lipase and amylase =< 2.0 x ULN and no radiologic (on baseline anatomical imaging) or clinical evidence of pancreatitis
  • Prior treatment with MET or VEGFR inhibitors is allowed. However, prior cabozantinib will not be allowed. Also, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are also not allowed
  • Prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4/CTLA-4 inhibitors is allowed, either in the perioperative or in the metastatic setting. However, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are not allowed
  • Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), no clinically significant drug-drug interactions are anticipated with the current HAART regimen, CD4 counts are greater than 350 and viral load is undetectable
  • Patients with rheumatoid arthritis and other rheumatologic arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication only and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies etc. are eligible but should be considered for rheumatologic evaluation for the presence of target organ involvement and potential need for systemic treatment
  • Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones or medications (e.g. thyroiditis managed with propylthiouracil [PTU] or methimazole) including physiologic oral corticosteroids are eligible
  • Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, and gastrointestinal (GI) obstruction, within 12 months are not eligible
  • Women of childbearing potential must have a negative pregnancy test =< 7 days prior to registration

    • Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post menopause is defined as amenorrhea >= 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason
  • Pregnant women may not participate in this study because with cabozantinib, nivolumab, and ipilimumab have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib, nivolumab, and ipilimumab, breastfeeding should be discontinued if the mother is treated with these agents
  • The patient has received no cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 2 weeks before the first dose of study treatment
  • The patient has received no radiation therapy:

    • To the lungs and mediastinum or abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy
    • To brain metastasis within 3 weeks for whole-brain radiotherapy (WBXRT), and 2 weeks for stereotactic body radiation therapy (SBRT) before the first dose of study treatment
    • To any other site(s) within 2 weeks before the first dose of study treatment
  • The patient has received no radionuclide treatment within 6 weeks of the first dose of study treatment
  • The patient has received no prior treatment with a small molecule kinase inhibitor within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
  • The patient has received no prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment. Subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate
  • The patient has not received any other type of investigational agent within 14 days before the first dose of study treatment
  • The patient must have recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non-clinically significant adverse events (AEs) defined as lab elevation with no associated symptoms or sequelae
  • The patient may not have active brain metastases or epidural disease. Patients with brain metastases previously treated with whole brain radiation or radiosurgery or subjects with epidural disease previously treated with radiation or surgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible. Neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment. Baseline brain imaging with contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) scans for subjects with known brain metastases is required to confirm eligibility
  • No concomitant treatment with warfarin. Aspirin (up to 325 mg/day), thrombin or factor Xa inhibitors, low-dose warfarin (=< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted
  • No chronic concomitant treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's wort) or strong CYP3A4 inhibitors

    • Because the lists of these agents are constantly changing, it is important to regularly consult medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • The patient has not experienced any of the following:

    • Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment
    • Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood per day within 1 months before the first dose of study treatment
    • Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
  • The patient has no tumor invading any major blood vessels
  • The patient has no evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib
  • The patient has no uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

    • Cardiovascular disorders including:

      • Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening.
      • Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment
      • The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 28 days before randomization. Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard
      • Any history of congenital long QT syndrome
      • Any of the following within 6 months before registration of study treatment:

        • Unstable angina pectoris
        • Clinically-significant cardiac arrhythmias (patients with atrial fibrillation are eligible)
        • Stroke (including transient ischemic attack [TIA], or other ischemic event)
        • Myocardial infarction
        • Cardiomyopathy
    • No significant gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:

      • Any of the following that have not resolved within 28 days before the first dose of study treatment:

        • Intra-abdominal tumor/metastases invading GI mucosa
        • Active peptic ulcer disease
        • Diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or malabsorption syndrome
      • None of the following within 1 year before the first dose of study treatment:

        • Abdominal fistula or genitourinary fistula
        • Gastrointestinal perforation
        • Bowel obstruction or gastric outlet obstruction
        • Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 12 months before the first dose of study treatment
    • Disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement are not eligible
    • No other clinically significant disorders such as:

      • Severe active infection requiring IV systemic treatment within 14 days before the first dose of study treatment
      • Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
      • History of organ or allogeneic stem cell transplant
      • Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid-stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)
    • No history of major surgery as follows:

      • Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery
      • Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and mediport placement
      • Complete wound healing from prior surgery must be confirmed before the first dose of cabozantinib irrespective of the time from surgery
  • No history of severe hypersensitivity reaction to any monoclonal antibody
  • No evidence of active malignancy, requiring systemic treatment within 2 years of registration
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study
  • No positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
  • No patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include, but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03866382


  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham Cancer Center Recruiting
Birmingham, Alabama, United States, 35233
Contact: Site Public Contact    205-934-0220    tmyrick@uab.edu   
Principal Investigator: Lakshminarayanan Nandagopal         
United States, Alaska
Anchorage Associates in Radiation Medicine Recruiting
Anchorage, Alaska, United States, 98508
Contact: Site Public Contact    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Alison K. Conlin         
Anchorage Radiation Therapy Center Recruiting
Anchorage, Alaska, United States, 99504
Contact: Site Public Contact    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Alison K. Conlin         
Alaska Breast Care and Surgery LLC Recruiting
Anchorage, Alaska, United States, 99508
Contact: Site Public Contact    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Alison K. Conlin         
Alaska Oncology and Hematology LLC Recruiting
Anchorage, Alaska, United States, 99508
Contact: Site Public Contact    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Alison K. Conlin         
Alaska Women's Cancer Care Recruiting
Anchorage, Alaska, United States, 99508
Contact: Site Public Contact    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Alison K. Conlin         
Anchorage Oncology Centre Recruiting
Anchorage, Alaska, United States, 99508
Contact: Site Public Contact    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Alison K. Conlin         
Katmai Oncology Group Recruiting
Anchorage, Alaska, United States, 99508
Contact: Site Public Contact    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Alison K. Conlin         
Providence Alaska Medical Center Recruiting
Anchorage, Alaska, United States, 99508
Contact: Site Public Contact    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Alison K. Conlin         
United States, Arizona
Kingman Regional Medical Center Recruiting
Kingman, Arizona, United States, 86401
Contact: Site Public Contact    888-823-5923    ctsucontact@westat.com   
Principal Investigator: John A. Ellerton         
Mayo Clinic Hospital Recruiting
Phoenix, Arizona, United States, 85054
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Lance C. Pagliaro         
Mayo Clinic in Arizona Recruiting
Scottsdale, Arizona, United States, 85259
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Lance C. Pagliaro         
United States, Arkansas
Mercy Hospital Fort Smith Recruiting
Fort Smith, Arkansas, United States, 72903
Contact: Site Public Contact    800-378-9373      
Principal Investigator: Jay W. Carlson         
CHI Saint Vincent Cancer Center Hot Springs Recruiting
Hot Springs, Arkansas, United States, 71913
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, California
PCR Oncology Recruiting
Arroyo Grande, California, United States, 93420
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Providence Saint Joseph Medical Center/Disney Family Cancer Center Recruiting
Burbank, California, United States, 91505
Contact: Site Public Contact    818-847-4793    Najee.Boucher@providence.org   
Principal Investigator: Alison K. Conlin         
Epic Care-Dublin Recruiting
Dublin, California, United States, 94568
Contact: Site Public Contact    925-875-1677      
Principal Investigator: Lisa Bailey         
Bay Area Breast Surgeons Inc Recruiting
Emeryville, California, United States, 94608
Contact: Site Public Contact    510-835-9900      
Principal Investigator: Lisa Bailey         
Epic Care Partners in Cancer Care Recruiting
Emeryville, California, United States, 94608
Contact: Site Public Contact    510-629-6682      
Principal Investigator: Lisa Bailey         
UCLA / Jonsson Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90095
Contact: Site Public Contact    888-798-0719      
Principal Investigator: Sandy T. Liu         
Contra Costa Regional Medical Center Recruiting
Martinez, California, United States, 94553-3156
Contact: Site Public Contact    925-957-5400      
Principal Investigator: Lisa Bailey         
Alta Bates Summit Medical Center - Summit Campus Recruiting
Oakland, California, United States, 94609
Contact: Site Public Contact    510-204-1414      
Principal Investigator: Lisa Bailey         
Bay Area Tumor Institute Recruiting
Oakland, California, United States, 94609
Contact: Site Public Contact    510-465-2242    lradke@bati.org   
Principal Investigator: Lisa Bailey         
Epic Care Cyberknife Center Recruiting
Walnut Creek, California, United States, 94597
Contact: Site Public Contact    510-465-8016    somega@bati.org   
Principal Investigator: Lisa Bailey         
United States, Colorado
Penrose-Saint Francis Healthcare Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Rocky Mountain Cancer Centers-Penrose Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Porter Adventist Hospital Recruiting
Denver, Colorado, United States, 80210
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Mercy Medical Center Recruiting
Durango, Colorado, United States, 81301
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Southwest Oncology PC Recruiting
Durango, Colorado, United States, 81301
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Saint Anthony Hospital Recruiting
Lakewood, Colorado, United States, 80228
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Littleton Adventist Hospital Recruiting
Littleton, Colorado, United States, 80122
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Longmont United Hospital Recruiting
Longmont, Colorado, United States, 80501
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Rocky Mountain Cancer Centers-Longmont Recruiting
Longmont, Colorado, United States, 80501
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Parker Adventist Hospital Recruiting
Parker, Colorado, United States, 80138
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Saint Mary Corwin Medical Center Recruiting
Pueblo, Colorado, United States, 81004
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, District of Columbia
MedStar Georgetown University Hospital Recruiting
Washington, District of Columbia, United States, 20007
Contact: Site Public Contact    202-444-2223      
Principal Investigator: Nancy A. Dawson         
United States, Florida
Mayo Clinic in Florida Recruiting
Jacksonville, Florida, United States, 32224-9980
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Lance C. Pagliaro         
UF Cancer Center at Orlando Health Recruiting
Orlando, Florida, United States, 32806
Contact: Site Public Contact    321-841-7246    CancerClinicalTrials@orlandohealth.com   
Principal Investigator: Daniel Landau         
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute Recruiting
Boise, Idaho, United States, 83712
Contact: Site Public Contact    208-381-2774    eslinget@slhs.org   
Principal Investigator: Alison K. Conlin         
Saint Alphonsus Cancer Care Center-Caldwell Recruiting
Caldwell, Idaho, United States, 83605
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Kootenai Medical Center Recruiting
Coeur d'Alene, Idaho, United States, 83814
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Walter Knox Memorial Hospital Recruiting
Emmett, Idaho, United States, 83617
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute - Fruitland Recruiting
Fruitland, Idaho, United States, 83619
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Alison K. Conlin         
Idaho Urologic Institute-Meridian Recruiting
Meridian, Idaho, United States, 83642
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute - Meridian Recruiting
Meridian, Idaho, United States, 83642
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Alison K. Conlin         
Saint Alphonsus Medical Center-Nampa Recruiting
Nampa, Idaho, United States, 83686
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute - Nampa Recruiting
Nampa, Idaho, United States, 83686
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Alison K. Conlin         
Kootenai Cancer Center Recruiting
Post Falls, Idaho, United States, 83854
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Kootenai Cancer Clinic Recruiting
Sandpoint, Idaho, United States, 83864
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute-Twin Falls Recruiting
Twin Falls, Idaho, United States, 83301
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Alison K. Conlin         
United States, Illinois
Rush - Copley Medical Center Recruiting
Aurora, Illinois, United States, 60504
Contact: Site Public Contact    630-978-6212    Cancer.Research@rushcopley.com   
Principal Investigator: Vamsi K. Vasireddy         
Illinois CancerCare-Bloomington Recruiting
Bloomington, Illinois, United States, 61704
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Canton Recruiting
Canton, Illinois, United States, 61520
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Memorial Hospital of Carbondale Recruiting
Carbondale, Illinois, United States, 62902
Contact: Site Public Contact    618-457-5200    clinical.research@sih.net   
Principal Investigator: Bryan A. Faller         
SIH Cancer Institute Recruiting
Carterville, Illinois, United States, 62918
Contact: Site Public Contact    618-985-3333    clinical.research@sih.net   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Carthage Recruiting
Carthage, Illinois, United States, 62321
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
University of Illinois Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact    312-355-3046      
Principal Investigator: David J. Peace         
University of Chicago Comprehensive Cancer Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Site Public Contact    773-702-8222    cancerclinicaltrials@bsd.uchicago.edu   
Principal Investigator: Walter M. Stadler         
Carle on Vermilion Recruiting
Danville, Illinois, United States, 61832
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
Cancer Care Specialists of Illinois - Decatur Recruiting
Decatur, Illinois, United States, 62526
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Decatur Memorial Hospital Recruiting
Decatur, Illinois, United States, 62526
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Dixon Recruiting
Dixon, Illinois, United States, 61021
Contact: Site Public Contact    815-285-7800      
Principal Investigator: Bryan A. Faller         
Carle Physician Group-Effingham Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
Crossroads Cancer Center Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Eureka Recruiting
Eureka, Illinois, United States, 61530
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Galesburg Recruiting
Galesburg, Illinois, United States, 61401
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Western Illinois Cancer Treatment Center Recruiting
Galesburg, Illinois, United States, 61401
Contact: Site Public Contact    309-344-2831      
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Kewanee Clinic Recruiting
Kewanee, Illinois, United States, 61443
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Macomb Recruiting
Macomb, Illinois, United States, 61455
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Carle Physician Group-Mattoon/Charleston Recruiting
Mattoon, Illinois, United States, 61938
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
Loyola University Medical Center Recruiting
Maywood, Illinois, United States, 60153
Contact: Site Public Contact    708-226-4357      
Principal Investigator: Stephanie A. Berg         
Marjorie Weinberg Cancer Center at Loyola-Gottlieb Recruiting
Melrose Park, Illinois, United States, 60160
Contact: Site Public Contact    708-450-4554      
Principal Investigator: Stephanie A. Berg         
Good Samaritan Regional Health Center Recruiting
Mount Vernon, Illinois, United States, 62864
Contact: Site Public Contact    618-242-4600      
Principal Investigator: Jay W. Carlson         
UC Comprehensive Cancer Center at Silver Cross Recruiting
New Lenox, Illinois, United States, 60451
Contact: Site Public Contact    773-702-8222    cancerclinicaltrials@bsd.uchicago.edu   
Principal Investigator: Walter M. Stadler         
University of Chicago Medicine-Orland Park Recruiting
Orland Park, Illinois, United States, 60462
Contact: Site Public Contact    773-702-8222    cancerclinicaltrials@bsd.uchicago.edu   
Principal Investigator: Walter M. Stadler         
Illinois CancerCare-Ottawa Clinic Recruiting
Ottawa, Illinois, United States, 61350
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Pekin Recruiting
Pekin, Illinois, United States, 61554
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Peoria Recruiting
Peoria, Illinois, United States, 61615
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Methodist Medical Center of Illinois Recruiting
Peoria, Illinois, United States, 61636
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Peru Recruiting
Peru, Illinois, United States, 61354
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Valley Radiation Oncology Recruiting
Peru, Illinois, United States, 61354
Contact: Site Public Contact    815-664-4141      
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Princeton Recruiting
Princeton, Illinois, United States, 61356
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Southern Illinois University School of Medicine Recruiting
Springfield, Illinois, United States, 62702
Contact: Site Public Contact    217-545-7929      
Principal Investigator: Bryan A. Faller         
Springfield Clinic Recruiting
Springfield, Illinois, United States, 62702
Contact: Site Public Contact    800-444-7541      
Principal Investigator: Bryan A. Faller         
Memorial Medical Center Recruiting
Springfield, Illinois, United States, 62781
Contact: Site Public Contact    217-788-3528      
Principal Investigator: Bryan A. Faller         
Cancer Care Specialists of Illinois-Swansea Recruiting
Swansea, Illinois, United States, 62226
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Southwest Illinois Health Services LLP Recruiting
Swansea, Illinois, United States, 62226
Contact: Site Public Contact    618-236-1000    lynns@thecancercenter.com   
Principal Investigator: Bryan A. Faller         
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
The Carle Foundation Hospital Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
Rush-Copley Healthcare Center Recruiting
Yorkville, Illinois, United States, 60560
Contact: Site Public Contact    630-978-6212    Cancer.Research@rushcopley.com   
Principal Investigator: Vamsi K. Vasireddy         
United States, Indiana
Reid Health Recruiting
Richmond, Indiana, United States, 47374
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
United States, Iowa
Mary Greeley Medical Center Recruiting
Ames, Iowa, United States, 50010
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
McFarland Clinic PC - Ames Recruiting
Ames, Iowa, United States, 50010
Contact: Site Public Contact    515-239-4734    ksoder@mcfarlandclinic.com   
Principal Investigator: Debra M. Prow         
McFarland Clinic PC-Boone Recruiting
Boone, Iowa, United States, 50036
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
Medical Oncology and Hematology Associates-West Des Moines Recruiting
Clive, Iowa, United States, 50325
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Mercy Cancer Center-West Lakes Recruiting
Clive, Iowa, United States, 50325
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Alegent Health Mercy Hospital Recruiting
Council Bluffs, Iowa, United States, 51503
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Greater Regional Medical Center Recruiting
Creston, Iowa, United States, 50801
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Medical Oncology and Hematology Associates-Laurel Recruiting
Des Moines, Iowa, United States, 50314
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Mercy Medical Center - Des Moines Recruiting
Des Moines, Iowa, United States, 50314
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
McFarland Clinic PC-Trinity Cancer Center Recruiting
Fort Dodge, Iowa, United States, 50501
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
McFarland Clinic PC-Jefferson Recruiting
Jefferson, Iowa, United States, 50129
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
McFarland Clinic PC-Marshalltown Recruiting
Marshalltown, Iowa, United States, 50158
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
Mercy Medical Center-West Lakes Recruiting
West Des Moines, Iowa, United States, 50266
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, Kansas
Cancer Center of Kansas - Chanute Recruiting
Chanute, Kansas, United States, 66720
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Dodge City Recruiting
Dodge City, Kansas, United States, 67801
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - El Dorado Recruiting
El Dorado, Kansas, United States, 67042
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
University of Kansas Clinical Research Center Recruiting
Fairway, Kansas, United States, 66205
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Elizabeth Wulff-Burchfield         
Hays Medical Center Recruiting
Hays, Kansas, United States, 67601
Contact: Site Public Contact    785-623-5774      
Principal Investigator: Elizabeth Wulff-Burchfield         
Cancer Center of Kansas-Independence Recruiting
Independence, Kansas, United States, 67301
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Kingman Recruiting
Kingman, Kansas, United States, 67068
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Lawrence Memorial Hospital Recruiting
Lawrence, Kansas, United States, 66044
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Liberal Recruiting
Liberal, Kansas, United States, 67905
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Manhattan Recruiting
Manhattan, Kansas, United States, 66502
Contact: Site Public Contact    316-268-5784    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - McPherson Recruiting
McPherson, Kansas, United States, 67460
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Newton Recruiting
Newton, Kansas, United States, 67114
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Olathe Medical Center Recruiting
Olathe, Kansas, United States, 66061
Contact: Site Public Contact    913-791-3500    Jeni.wakefield@olathehealth.org   
Principal Investigator: Elizabeth Wulff-Burchfield         
Cancer Center of Kansas - Parsons Recruiting
Parsons, Kansas, United States, 67357
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Via Christi Hospital-Pittsburg Recruiting
Pittsburg, Kansas, United States, 66762
Contact: Site Public Contact    620-235-7900      
Principal Investigator: Elizabeth Wulff-Burchfield         
Cancer Center of Kansas - Pratt Recruiting
Pratt, Kansas, United States, 67124
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Salina Recruiting
Salina, Kansas, United States, 67401
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Salina Regional Health Center Recruiting
Salina, Kansas, United States, 67401
Contact: Site Public Contact    785-452-7038    kkavoura@srhc.com   
Principal Investigator: Elizabeth Wulff-Burchfield         
Saint Francis Hospital and Medical Center - Topeka Recruiting
Topeka, Kansas, United States, 66606
Contact: Site Public Contact    785-295-8000      
Principal Investigator: Elizabeth Wulff-Burchfield         
Cancer Center of Kansas - Wellington Recruiting
Wellington, Kansas, United States, 67152
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
University of Kansas Hospital-Westwood Cancer Center Recruiting
Westwood, Kansas, United States, 66205
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Elizabeth Wulff-Burchfield         
Cancer Center of Kansas-Wichita Medical Arts Tower Recruiting
Wichita, Kansas, United States, 67208
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Ascension Via Christi Hospitals Wichita Recruiting
Wichita, Kansas, United States, 67214
Contact: Site Public Contact    800-362-0070    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Wichita Recruiting
Wichita, Kansas, United States, 67214
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Winfield Recruiting
Winfield, Kansas, United States, 67156
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
United States, Kentucky
Flaget Memorial Hospital Recruiting
Bardstown, Kentucky, United States, 40004
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Commonwealth Cancer Center-Corbin Recruiting
Corbin, Kentucky, United States, 40701
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Saint Joseph Radiation Oncology Resource Center Recruiting
Lexington, Kentucky, United States, 40504
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Saint Joseph Hospital East Recruiting
Lexington, Kentucky, United States, 40509
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Saint Joseph London Recruiting
London, Kentucky, United States, 40741
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Jewish Hospital Recruiting
Louisville, Kentucky, United States, 40202
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Saints Mary and Elizabeth Hospital Recruiting
Louisville, Kentucky, United States, 40215
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Jewish Hospital Medical Center Northeast Recruiting
Louisville, Kentucky, United States, 40245
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Jewish Hospital Medical Center South Recruiting
Shepherdsville, Kentucky, United States, 40165
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, Louisiana
East Jefferson General Hospital Recruiting
Metairie, Louisiana, United States, 70006
Contact: Site Public Contact    504-210-3539    emede1@lsuhsc.edu   
Principal Investigator: Scott E. Delacroix         
LSU Healthcare Network / Metairie Multi-Specialty Clinic Recruiting
Metairie, Louisiana, United States, 70006
Contact: Site Public Contact    504-210-3539    emede1@lsuhsc.edu   
Principal Investigator: Scott E. Delacroix         
Louisiana State University Health Science Center Recruiting
New Orleans, Louisiana, United States, 70112
Contact: Site Public Contact    504-210-3539    emede1@lsuhsc.edu   
Principal Investigator: Scott E. Delacroix         
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: Site Public Contact    800-411-1222      
Principal Investigator: Andrea B. Apolo         
United States, Massachusetts
Lahey Hospital and Medical Center Recruiting
Burlington, Massachusetts, United States, 01805
Contact: Site Public Contact    781-744-3421    cancerclinicaltrials@lahey.org   
Principal Investigator: Brendan Connell         
Mercy Medical Center Recruiting
Springfield, Massachusetts, United States, 01104
Contact: Site Public Contact    413-748-9234      
Principal Investigator: Tareq Al Baghdadi         
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
IHA Hematology Oncology Consultants-Brighton Recruiting
Brighton, Michigan, United States, 48114
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Joseph Mercy Brighton Recruiting
Brighton, Michigan, United States, 48114
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Henry Ford Cancer Institute-Downriver Recruiting
Brownstown, Michigan, United States, 48183
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
IHA Hematology Oncology Consultants-Canton Recruiting
Canton, Michigan, United States, 48188
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Joseph Mercy Canton Recruiting
Canton, Michigan, United States, 48188
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Caro Cancer Center Recruiting
Caro, Michigan, United States, 48723
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
IHA Hematology Oncology Consultants-Chelsea Recruiting
Chelsea, Michigan, United States, 48118
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Joseph Mercy Chelsea Recruiting
Chelsea, Michigan, United States, 48118
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Hematology Oncology Consultants-Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Newland Medical Associates-Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Henry Ford Macomb Hospital-Clinton Township Recruiting
Clinton Township, Michigan, United States, 48038
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Henry Ford Medical Center-Fairlane Recruiting
Dearborn, Michigan, United States, 48126
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Ascension Saint John Hospital Recruiting
Detroit, Michigan, United States, 48236
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Great Lakes Cancer Management Specialists-Doctors Park Recruiting
East China Township, Michigan, United States, 48054
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Genesee Cancer and Blood Disease Treatment Center Recruiting
Flint, Michigan, United States, 48503
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Genesee Hematology Oncology PC Recruiting
Flint, Michigan, United States, 48503
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Genesys Hurley Cancer Institute Recruiting
Flint, Michigan, United States, 48503
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Hurley Medical Center Recruiting
Flint, Michigan, United States, 48503
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Academic Hematology Oncology Specialists Recruiting
Grosse Pointe Woods, Michigan, United States, 48236
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center Recruiting
Grosse Pointe Woods, Michigan, United States, 48236
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Michigan Breast Specialists-Grosse Pointe Woods Recruiting
Grosse Pointe Woods, Michigan, United States, 48236
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Allegiance Health Recruiting
Jackson, Michigan, United States, 49201
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Sparrow Hospital Recruiting
Lansing, Michigan, United States, 48912
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Hope Cancer Clinic Recruiting
Livonia, Michigan, United States, 48154
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Mary Mercy Hospital Recruiting
Livonia, Michigan, United States, 48154
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Great Lakes Cancer Management Specialists-Macomb Medical Campus Recruiting
Macomb, Michigan, United States, 48044
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Michigan Breast Specialists-Macomb Township Recruiting
Macomb, Michigan, United States, 48044
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Mary's Oncology/Hematology Associates of Marlette Recruiting
Marlette, Michigan, United States, 48453
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Henry Ford Medical Center-Columbus Recruiting
Novi, Michigan, United States, 48377
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
21st Century Oncology-Pontiac Recruiting
Pontiac, Michigan, United States, 48341
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Hope Cancer Center Recruiting
Pontiac, Michigan, United States, 48341
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Newland Medical Associates-Pontiac Recruiting
Pontiac, Michigan, United States, 48341
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint Joseph Mercy Oakland Recruiting
Pontiac, Michigan, United States, 48341
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Huron Medical Center PC Suspended
Port Huron, Michigan, United States, 48060
Lake Huron Medical Center Suspended
Port Huron, Michigan, United States, 48060
Great Lakes Cancer Management Specialists-Rochester Hills Recruiting
Rochester Hills, Michigan, United States, 48309
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Ascension Saint Mary's Hospital Recruiting
Saginaw, Michigan, United States, 48601
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Oncology Hematology Associates of Saginaw Valley PC Recruiting
Saginaw, Michigan, United States, 48604
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Bhadresh Nayak MD PC-Sterling Heights Recruiting
Sterling Heights, Michigan, United States, 48312
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Ascension Saint Joseph Hospital Recruiting
Tawas City, Michigan, United States, 48764
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Advanced Breast Care Center PLLC Recruiting
Warren, Michigan, United States, 48088
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Great Lakes Cancer Management Specialists-Macomb Professional Building Recruiting
Warren, Michigan, United States, 48093
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Macomb Hematology Oncology PC Recruiting
Warren, Michigan, United States, 48093
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Michigan Breast Specialists-Warren Recruiting
Warren, Michigan, United States, 48093
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Saint John Macomb-Oakland Hospital Recruiting
Warren, Michigan, United States, 48093
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Henry Ford West Bloomfield Hospital Recruiting
West Bloomfield, Michigan, United States, 48322
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Saint Mary's Oncology/Hematology Associates of West Branch Recruiting
West Branch, Michigan, United States, 48661
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Huron Gastroenterology PC Recruiting
Ypsilanti, Michigan, United States, 48106
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
IHA Hematology Oncology Consultants-Ann Arbor Recruiting
Ypsilanti, Michigan, United States, 48197
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
United States, Minnesota
Fairview Ridges Hospital Recruiting
Burnsville, Minnesota, United States, 55337
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Cambridge Medical Center Recruiting
Cambridge, Minnesota, United States, 55008
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Mercy Hospital Recruiting
Coon Rapids, Minnesota, United States, 55433
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Fairview-Southdale Hospital Recruiting
Edina, Minnesota, United States, 55435
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Unity Hospital Recruiting
Fridley, Minnesota, United States, 55432
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Fairview Maple Grove Medical Center Recruiting
Maple Grove, Minnesota, United States, 55369
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Minnesota Oncology Hematology PA-Maplewood Recruiting
Maplewood, Minnesota, United States, 55109
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Saint John's Hospital - Healtheast Recruiting
Maplewood, Minnesota, United States, 55109
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Abbott-Northwestern Hospital Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Hennepin County Medical Center Recruiting
Minneapolis, Minnesota, United States, 55415
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Health Partners Inc Recruiting
Minneapolis, Minnesota, United States, 55454
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Monticello Cancer Center Recruiting
Monticello, Minnesota, United States, 55362
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
New Ulm Medical Center Recruiting
New Ulm, Minnesota, United States, 56073
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Fairview Northland Medical Center Recruiting
Princeton, Minnesota, United States, 55371
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
North Memorial Medical Health Center Recruiting
Robbinsdale, Minnesota, United States, 55422
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Lance C. Pagliaro         
Park Nicollet Clinic - Saint Louis Park Recruiting
Saint Louis Park, Minnesota, United States, 55416
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Regions Hospital Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
United Hospital Recruiting
Saint Paul, Minnesota, United States, 55102
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Saint Francis Regional Medical Center Recruiting
Shakopee, Minnesota, United States, 55379
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Lakeview Hospital Recruiting
Stillwater, Minnesota, United States, 55082
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Ridgeview Medical Center Recruiting
Waconia, Minnesota, United States, 55387
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Rice Memorial Hospital Recruiting
Willmar, Minnesota, United States, 56201
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Minnesota Oncology Hematology PA-Woodbury Recruiting
Woodbury, Minnesota, United States, 55125
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
Fairview Lakes Medical Center Recruiting
Wyoming, Minnesota, United States, 55092
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
United States, Mississippi
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 39216
Contact: Site Public Contact    601-815-6700      
Principal Investigator: John C. Henegan         
United States, Missouri
Saint Louis Cancer and Breast Institute-Ballwin Recruiting
Ballwin, Missouri, United States, 63011
Contact: Site Public Contact    314-251-7058      
Principal Investigator: Jay W. Carlson         
Parkland Health Center-Bonne Terre Recruiting
Bonne Terre, Missouri, United States, 63628
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Cox Cancer Center Branson Recruiting
Branson, Missouri, United States, 65616
Contact: Site Public Contact    417-269-4520      
Principal Investigator: Jay W. Carlson         
Saint Francis Medical Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: Site Public Contact    573-334-2230    sfmc@sfmc.net   
Principal Investigator: Bryan A. Faller         
Southeast Cancer Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: Site Public Contact    573-651-5550      
Principal Investigator: Bryan A. Faller         
Parkland Health Center - Farmington Recruiting
Farmington, Missouri, United States, 63640
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Capital Region Southwest Campus Recruiting
Jefferson City, Missouri, United States, 65109
Contact: Site Public Contact    573-632-4814    swooden@mail.crmc.org   
Principal Investigator: Bryan A. Faller         
Freeman Health System Recruiting
Joplin, Missouri, United States, 64804
Contact: Site Public Contact    417-347-4030    LJCrockett@freemanhealth.com   
Principal Investigator: Jay W. Carlson         
Mercy Hospital Joplin Recruiting
Joplin, Missouri, United States, 64804
Contact: Site Public Contact    417-556-3074    esmeralda.carrillo@mercy.net   
Principal Investigator: Jay W. Carlson         
Truman Medical Center Recruiting
Kansas City, Missouri, United States, 64108
Contact: Site Public Contact    816-404-4375      
Principal Investigator: Elizabeth Wulff-Burchfield         
Delbert Day Cancer Institute at PCRMC Recruiting
Rolla, Missouri, United States, 65401
Contact: Site Public Contact    573-458-7504    jrichards@research.pcrmc.com   
Principal Investigator: Jay W. Carlson         
Mercy Clinic-Rolla-Cancer and Hematology Recruiting
Rolla, Missouri, United States, 65401
Contact: Site Public Contact    573-458-7504    jrichards@research.pcrmc.com   
Principal Investigator: Jay W. Carlson         
Heartland Regional Medical Center Recruiting
Saint Joseph, Missouri, United States, 64507
Contact: Site Public Contact    816-271-7937    linda.schumacher@mymlc.com   
Principal Investigator: Jay W. Carlson         
Saint Louis Cancer and Breast Institute-South City Recruiting
Saint Louis, Missouri, United States, 63109
Contact: Site Public Contact    314-353-1870      
Principal Investigator: Jay W. Carlson         
Mercy Hospital South Recruiting
Saint Louis, Missouri, United States, 63128
Contact: Site Public Contact       janet.lesko@mercy.net   
Principal Investigator: Jay W. Carlson         
Missouri Baptist Medical Center Recruiting
Saint Louis, Missouri, United States, 63131
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Mercy Hospital Saint Louis Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Site Public Contact    314-251-7066      
Principal Investigator: Jay W. Carlson         
Sainte Genevieve County Memorial Hospital Recruiting
Sainte Genevieve, Missouri, United States, 63670
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Mercy Hospital Springfield Recruiting
Springfield, Missouri, United States, 65804
Contact: Site Public Contact    417-269-4520      
Principal Investigator: Jay W. Carlson         
CoxHealth South Hospital Recruiting
Springfield, Missouri, United States, 65807
Contact: Site Public Contact    417-269-4520      
Principal Investigator: Jay W. Carlson         
Missouri Baptist Sullivan Hospital Recruiting
Sullivan, Missouri, United States, 63080
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Missouri Baptist Outpatient Center-Sunset Hills Recruiting
Sunset Hills, Missouri, United States, 63127
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Mercy Hospital Washington Recruiting
Washington, Missouri, United States, 63090
Contact: Site Public Contact    636-390-1600      
Principal Investigator: Jay W. Carlson         
United States, Montana
Community Hospital of Anaconda Recruiting
Anaconda, Montana, United States, 59711
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Billings Clinic Cancer Center Recruiting
Billings, Montana, United States, 59101
Contact: Site Public Contact    800-996-2663    research@billingsclinic.org   
Principal Investigator: John M. Schallenkamp         
Bozeman Deaconess Hospital Recruiting
Bozeman, Montana, United States, 59715
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Benefis Healthcare- Sletten Cancer Institute Recruiting
Great Falls, Montana, United States, 59405
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Great Falls Clinic Recruiting
Great Falls, Montana, United States, 59405
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Saint Peter's Community Hospital Suspended
Helena, Montana, United States, 59601
Kalispell Regional Medical Center Recruiting
Kalispell, Montana, United States, 59901
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Saint Patrick Hospital - Community Hospital Recruiting
Missoula, Montana, United States, 59802
Contact: Site Public Contact    406-327-3118    amy.hanneman@providence.org   
Principal Investigator: Alison K. Conlin         
Community Medical Hospital Recruiting
Missoula, Montana, United States, 59804
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
United States, Nebraska
CHI Health Saint Francis Recruiting
Grand Island, Nebraska, United States, 68803
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
CHI Health Good Samaritan Recruiting
Kearney, Nebraska, United States, 68847
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Saint Elizabeth Regional Medical Center Recruiting
Lincoln, Nebraska, United States, 68510
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Nebraska Methodist Hospital Recruiting
Omaha, Nebraska, United States, 68114
Contact: Site Public Contact    402-354-5144      
Principal Investigator: Ralph J. Hauke         
Alegent Health Immanuel Medical Center Recruiting
Omaha, Nebraska, United States, 68122
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Alegent Health Bergan Mercy Medical Center Recruiting
Omaha, Nebraska, United States, 68124
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Alegent Health Lakeside Hospital Recruiting
Omaha, Nebraska, United States, 68130
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Creighton University Medical Center Recruiting
Omaha, Nebraska, United States, 68131
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Midlands Community Hospital Recruiting
Papillion, Nebraska, United States, 68046
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, Nevada
Carson Tahoe Regional Medical Center Recruiting
Carson City, Nevada, United States, 89703
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Cancer and Blood Specialists-Henderson Recruiting
Henderson, Nevada, United States, 89052
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada - Henderson Recruiting
Henderson, Nevada, United States, 89052
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada-Horizon Ridge Recruiting
Henderson, Nevada, United States, 89052
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Cancer Center-Henderson Recruiting
Henderson, Nevada, United States, 89052
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
OptumCare Cancer Care at Seven Hills Recruiting
Henderson, Nevada, United States, 89052
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
21st Century Oncology-Henderson Recruiting
Henderson, Nevada, United States, 89074
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada-Southeast Henderson Recruiting
Henderson, Nevada, United States, 89074
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Urology - Green Valley Recruiting
Henderson, Nevada, United States, 89074
Contact: Site Public Contact       research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Urology - Pebble Recruiting
Henderson, Nevada, United States, 89074
Contact: Site Public Contact       research@sncrf.org   
Principal Investigator: John A. Ellerton         
Urology Specialists of Nevada - Green Valley Recruiting
Henderson, Nevada, United States, 89074
Contact: Site Public Contact       research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Urology - Pecos Recruiting
Las Vegas, Nevada, United States, 89074
Contact: Site Public Contact       research@sncrf.org   
Principal Investigator: John A. Ellerton         
Desert West Surgery Recruiting
Las Vegas, Nevada, United States, 89102
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
University Medical Center of Southern Nevada Recruiting
Las Vegas, Nevada, United States, 89102
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Hope Cancer Care of Nevada Recruiting
Las Vegas, Nevada, United States, 89103
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Cancer and Blood Specialists-Shadow Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
OptumCare Cancer Care at Oakey Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Radiation Oncology Centers of Nevada Central Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Urology Specialists of Nevada - Central Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Site Public Contact       research@sncrf.org   
Principal Investigator: John A. Ellerton         
21st Century Oncology Recruiting
Las Vegas, Nevada, United States, 89109
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway Recruiting
Las Vegas, Nevada, United States, 89109
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Sunrise Hospital and Medical Center Recruiting
Las Vegas, Nevada, United States, 89109
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
HealthCare Partners Medical Group Oncology/Hematology-San Martin Recruiting
Las Vegas, Nevada, United States, 89113
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Prostate Cancer Center Recruiting
Las Vegas, Nevada, United States, 89113
Contact: Site Public Contact       research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Urology - Sunset Recruiting
Las Vegas, Nevada, United States, 89113
Contact: Site Public Contact       research@sncrf.org   
Principal Investigator: John A. Ellerton         
Radiation Oncology Centers of Nevada Southeast Recruiting
Las Vegas, Nevada, United States, 89119
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
21st Century Oncology-Vegas Tenaya Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Ann M Wierman MD LTD Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Cancer and Blood Specialists-Tenaya Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada - Northwest Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
HealthCare Partners Medical Group Oncology/Hematology-Tenaya Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Urology - Cathedral Rock Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Site Public Contact       research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Urology - Smoke Ranch Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Site Public Contact       research@smcrf.org   
Principal Investigator: John A. Ellerton         
OptumCare Cancer Care at MountainView Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Urology Specialists of Nevada - Northwest Recruiting
Las Vegas, Nevada, United States, 89128
Contact: Site Public Contact       research@sncrf.org   
Principal Investigator: John A. Ellerton         
Alliance for Childhood Diseases/Cure 4 the Kids Foundation Recruiting
Las Vegas, Nevada, United States, 89135
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada - Town Center Recruiting
Las Vegas, Nevada, United States, 89144
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada-Summerlin Recruiting
Las Vegas, Nevada, United States, 89144
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Summerlin Hospital Medical Center Recruiting
Las Vegas, Nevada, United States, 89144
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Cancer Center-Medical Center Recruiting
Las Vegas, Nevada, United States, 89148-2405
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
21st Century Oncology-Fort Apache Recruiting
Las Vegas, Nevada, United States, 89148
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada Recruiting
Las Vegas, Nevada, United States, 89148
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
OptumCare Cancer Care at Fort Apache Recruiting
Las Vegas, Nevada, United States, 89148
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Urology Specialists of Nevada - Southwest Recruiting
Las Vegas, Nevada, United States, 89148
Contact: Site Public Contact       research@sncrf.org   
Principal Investigator: John A. Ellerton         
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills Recruiting
Las Vegas, Nevada, United States, 89149
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada - Central Valley Recruiting
Las Vegas, Nevada, United States, 89169
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
University Cancer Center Recruiting
Las Vegas, Nevada, United States, 89169
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Hope Cancer Care of Nevada-Pahrump Recruiting
Pahrump, Nevada, United States, 89048
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Renown Regional Medical Center Recruiting
Reno, Nevada, United States, 89502
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Saint Mary's Regional Medical Center Recruiting
Reno, Nevada, United States, 89503
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Radiation Oncology Associates Recruiting
Reno, Nevada, United States, 89509
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
United States, New York
Roswell Park Cancer Institute Not yet recruiting
Buffalo, New York, United States, 14263
Contact: Site Public Contact    800-767-9355    askroswell@roswellpark.org   
Principal Investigator: Ellis G. Levine         
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center Recruiting
New York, New York, United States, 10032
Contact: Site Public Contact    212-305-6361    nr2616@cumc.columbia.edu   
Principal Investigator: Emerson A. Lim         
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Site Public Contact    585-275-5830      
Principal Investigator: Paul M. Barr         
United States, North Carolina
UNC Lineberger Comprehensive Cancer Center Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Site Public Contact    877-668-0683    cancerclinicaltrials@med.unc.edu   
Principal Investigator: Tracy L. Rose         
Margaret R Pardee Memorial Hospital Recruiting
Hendersonville, North Carolina, United States, 28791
Contact: Site Public Contact    828-696-4716    karen.morris@unchealth.unc.edu   
Principal Investigator: James E. Radford         
United States, Ohio
Indu and Raj Soin Medical Center Recruiting
Beavercreek, Ohio, United States, 45431
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Strecker Cancer Center-Belpre Recruiting
Belpre, Ohio, United States, 45714
Contact: Site Public Contact    800-523-3977    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Saint Elizabeth Boardman Hospital Recruiting
Boardman, Ohio, United States, 44512
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Dayton Physicians LLC-Miami Valley South Recruiting
Centerville, Ohio, United States, 45459
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Miami Valley Hospital South Recruiting
Centerville, Ohio, United States, 45459
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Adena Regional Medical Center Recruiting
Chillicothe, Ohio, United States, 45601
Contact: Site Public Contact    877-779-7585    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Good Samaritan Hospital - Cincinnati Recruiting
Cincinnati, Ohio, United States, 45220
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Oncology Hematology Care Inc-Kenwood Recruiting
Cincinnati, Ohio, United States, 45236
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Bethesda North Hospital Recruiting
Cincinnati, Ohio, United States, 45242
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
TriHealth Cancer Institute-Westside Recruiting
Cincinnati, Ohio, United States, 45247
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
TriHealth Cancer Institute-Anderson Recruiting
Cincinnati, Ohio, United States, 45255
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu   
Principal Investigator: Amir Mortazavi         
Mount Carmel East Hospital Recruiting
Columbus, Ohio, United States, 43213
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Columbus Oncology and Hematology Associates Inc Recruiting
Columbus, Ohio, United States, 43214
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Riverside Methodist Hospital Recruiting
Columbus, Ohio, United States, 43214
Contact: Site Public Contact    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Grant Medical Center Recruiting
Columbus, Ohio, United States, 43215
Contact: Site Public Contact    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Mount Carmel Health Center West Recruiting
Columbus, Ohio, United States, 43222
Contact: Site Public Contact    614-234-5433    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Doctors Hospital Recruiting
Columbus, Ohio, United States, 43228
Contact: Site Public Contact    614-566-3275    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Good Samaritan Hospital - Dayton Recruiting
Dayton, Ohio, United States, 45406
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Miami Valley Hospital Recruiting
Dayton, Ohio, United States, 45409
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Dayton Physician LLC-Miami Valley Hospital North Recruiting
Dayton, Ohio, United States, 45415
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Miami Valley Hospital North Recruiting
Dayton, Ohio, United States, 45415
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Delaware Health Center-Grady Cancer Center Recruiting
Delaware, Ohio, United States, 43015
Contact: Site Public Contact    740-615-0227    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Grady Memorial Hospital Recruiting
Delaware, Ohio, United States, 43015
Contact: Site Public Contact    740-615-2403    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Dublin Methodist Hospital Recruiting
Dublin, Ohio, United States, 43016
Contact: Site Public Contact    800-752-9119    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Armes Family Cancer Center Recruiting
Findlay, Ohio, United States, 45840
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Blanchard Valley Hospital Recruiting
Findlay, Ohio, United States, 45840
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Orion Cancer Care Recruiting
Findlay, Ohio, United States, 45840
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Atrium Medical Center-Middletown Regional Hospital Recruiting
Franklin, Ohio, United States, 45005-1066
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Dayton Physicians LLC-Atrium Recruiting
Franklin, Ohio, United States, 45005
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Central Ohio Breast and Endocrine Surgery Recruiting
Gahanna, Ohio, United States, 43230
Contact: Site Public Contact    614-488-2745    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Dayton Physicians LLC-Wayne Recruiting
Greenville, Ohio, United States, 45331
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Wayne Hospital Recruiting
Greenville, Ohio, United States, 45331
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Greater Dayton Cancer Center Recruiting
Kettering, Ohio, United States, 45409
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
First Dayton Cancer Care Recruiting
Kettering, Ohio, United States, 45420
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Kettering Medical Center Recruiting
Kettering, Ohio, United States, 45429
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Fairfield Medical Center Recruiting
Lancaster, Ohio, United States, 43130
Contact: Site Public Contact    740-687-8863    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
OhioHealth Mansfield Hospital Recruiting
Mansfield, Ohio, United States, 44903
Contact: Site Public Contact    419-526-8018    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Marietta Memorial Hospital Recruiting
Marietta, Ohio, United States, 45750
Contact: Site Public Contact    800-523-3977    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
OhioHealth Marion General Hospital Recruiting
Marion, Ohio, United States, 43302
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Knox Community Hospital Recruiting
Mount Vernon, Ohio, United States, 43050
Contact: Site Public Contact    740-393-9000    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Licking Memorial Hospital Recruiting
Newark, Ohio, United States, 43055
Contact: Site Public Contact    740-348-4000    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Newark Radiation Oncology Recruiting
Newark, Ohio, United States, 43055
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Southern Ohio Medical Center Recruiting
Portsmouth, Ohio, United States, 45662
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Springfield Regional Cancer Center Recruiting
Springfield, Ohio, United States, 45504
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Springfield Regional Medical Center Recruiting
Springfield, Ohio, United States, 45505
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Dayton Physicians LLC-Upper Valley Recruiting
Troy, Ohio, United States, 45373
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Upper Valley Medical Center Recruiting
Troy, Ohio, United States, 45373
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Saint Joseph Warren Hospital Recruiting
Warren, Ohio, United States, 44484
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Saint Ann's Hospital Recruiting
Westerville, Ohio, United States, 43081
Contact: Site Public Contact    614-234-5433    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Saint Elizabeth Youngstown Hospital Recruiting
Youngstown, Ohio, United States, 44501
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Genesis Healthcare System Cancer Care Center Recruiting
Zanesville, Ohio, United States, 43701
Contact: Site Public Contact    740-454-5232    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
United States, Oklahoma
Cancer Centers of Southwest Oklahoma Research Recruiting
Lawton, Oklahoma, United States, 73505
Contact: Site Public Contact    877-231-4440      
Principal Investigator: Abhishek Tripathi         
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Abhishek Tripathi         
Mercy Hospital Oklahoma City Recruiting
Oklahoma City, Oklahoma, United States, 73120
Contact: Site Public Contact    405-752-3402      
Principal Investigator: Jay W. Carlson         
Oklahoma Cancer Specialists and Research Institute-Tulsa Recruiting
Tulsa, Oklahoma, United States, 74146
Contact: Site Public Contact    918-505-3200      
Principal Investigator: Abhishek Tripathi         
United States, Oregon
Saint Alphonsus Medical Center-Baker City Recruiting
Baker City, Oregon, United States, 97814
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Charles Health System Recruiting
Bend, Oregon, United States, 97701
Contact: Site Public Contact    541-706-2909    nosall@stcharleshealthcare.org   
Principal Investigator: Alison K. Conlin         
Clackamas Radiation Oncology Center Recruiting
Clackamas, Oregon, United States, 97015
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Alison K. Conlin         
Providence Oncology and Hematology Care Southeast Recruiting
Clackamas, Oregon, United States, 97015
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Alison K. Conlin         
Bay Area Hospital Recruiting
Coos Bay, Oregon, United States, 97420
Contact: Site Public Contact    541-269-8392    cherie.cox@bayareahospital.org   
Principal Investigator: Alison K. Conlin         
Providence Newberg Medical Center Recruiting
Newberg, Oregon, United States, 97132
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Alison K. Conlin         
Saint Alphonsus Medical Center-Ontario Recruiting
Ontario, Oregon, United States, 97914
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Alison K. Conlin         
Providence Saint Vincent Medical Center Recruiting
Portland, Oregon, United States, 97225
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Alison K. Conlin         
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Site Public Contact    503-494-1080    trials@ohsu.edu   
Principal Investigator: Christopher W. Ryan         
Saint Charles Health System-Redmond Recruiting
Redmond, Oregon, United States, 97756
Contact: Site Public Contact    541-706-2909      
Principal Investigator: Alison K. Conlin         
United States, Pennsylvania
Lehigh Valley Hospital-Cedar Crest Recruiting
Allentown, Pennsylvania, United States, 18103
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Lehigh Valley Hospital - Muhlenberg Recruiting
Bethlehem, Pennsylvania, United States, 18017
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Tareq Al Baghdadi         
Pocono Medical Center Recruiting
East Stroudsburg, Pennsylvania, United States, 18301
Contact: Site Public Contact    570-422-1700    ann.foster@lvhn.org   
Principal Investigator: Tareq Al Baghdadi         
Lehigh Valley Hospital-Hazleton Recruiting
Hazleton, Pennsylvania, United States, 18201
Contact: Site Public Contact    570-501-1242      
Principal Investigator: Tareq Al Baghdadi         
University of Pittsburgh Cancer Institute (UPCI) Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Site Public Contact    412-647-8073      
Principal Investigator: Leonard J. Appleman         
UPMC-Shadyside Hospital Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Site Public Contact    412-621-2334      
Principal Investigator: Leonard J. Appleman         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Site Public Contact    843-792-9321    hcc-clinical-trials@musc.edu   
Principal Investigator: Theodore S. Gourdin         
United States, Texas
Saint Joseph Regional Cancer Center Recruiting
Bryan, Texas, United States, 77802
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
UT Southwestern/Simmons Cancer Center-Dallas Recruiting
Dallas, Texas, United States, 75390
Contact: Site Public Contact    214-648-7097    canceranswerline@UTSouthwestern.edu   
Principal Investigator: Suzanne M. Cole         
UT Southwestern/Simmons Cancer Center-Fort Worth Recruiting
Fort Worth, Texas, United States, 76104
Contact: Site Public Contact    214-648-7097    canceranswerline@UTSouthwestern.edu   
Principal Investigator: Suzanne M. Cole         
UT Southwestern Clinical Center at Richardson/Plano Recruiting
Richardson, Texas, United States, 75080
Contact: Site Public Contact    972-669-7044    Suzanne.cole@utsouthwestern.edu   
Principal Investigator: Suzanne M. Cole         
United States, Washington
Providence Regional Cancer System-Aberdeen Recruiting
Aberdeen, Washington, United States, 98520
Contact: Site Public Contact    360-412-8958    deidre.dillon@providence.org   
Principal Investigator: Alison K. Conlin         
Overlake Hospital Medical Center Recruiting
Bellevue, Washington, United States, 98004
Contact: Site Public Contact    425-688-5407    OHMCResearch@overlakehospital.org   
Principal Investigator: John A. Ellerton         
PeaceHealth Saint Joseph Medical Center Recruiting
Bellingham, Washington, United States, 98225
Contact: Site Public Contact    360-715-4133    mjohnson9@peacehealth.org   
Principal Investigator: Alison K. Conlin         
Harrison HealthPartners Hematology and Oncology-Bremerton Recruiting
Bremerton, Washington, United States, 98310
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Harrison Medical Center Recruiting
Bremerton, Washington, United States, 98310
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Highline Medical Center-Main Campus Recruiting
Burien, Washington, United States, 98166
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Providence Regional Cancer System-Centralia Recruiting
Centralia, Washington, United States, 98531
Contact: Site Public Contact    360-412-8958    deidre.dillon@providence.org   
Principal Investigator: Alison K. Conlin         
Swedish Cancer Institute-Edmonds Recruiting
Edmonds, Washington, United States, 98026
Contact: Site Public Contact    206-215-3086    PCRC-NCORP@Swedish.org   
Principal Investigator: Alison K. Conlin         
Saint Elizabeth Hospital Recruiting
Enumclaw, Washington, United States, 98022
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Providence Regional Cancer Partnership Recruiting
Everett, Washington, United States, 98201
Contact: Site Public Contact    425-261-3529    marilyn.birchman@providence.org   
Principal Investigator: Alison K. Conlin         
Saint Francis Hospital Recruiting
Federal Way, Washington, United States, 98003
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Swedish Cancer Institute-Issaquah Recruiting
Issaquah, Washington, United States, 98029
Contact: Site Public Contact    206-215-3086    PCRC-NCORP@Swedish.org   
Principal Investigator: Alison K. Conlin         
Kadlec Clinic Hematology and Oncology Recruiting
Kennewick, Washington, United States, 99336
Contact: Site Public Contact    509-783-4637    research@kadlecmed.org   
Principal Investigator: Alison K. Conlin         
Providence Regional Cancer System-Lacey Recruiting
Lacey, Washington, United States, 98503
Contact: Site Public Contact    360-412-8958    deidre.dillon@providence.org   
Principal Investigator: Alison K. Conlin         
Saint Clare Hospital Recruiting
Lakewood, Washington, United States, 98499
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
PeaceHealth Saint John Medical Center Recruiting
Longview, Washington, United States, 98632
Contact: Site Public Contact    360-514-2016    kmakin-bond@peacehealth.org   
Principal Investigator: Alison K. Conlin         
Harrison HealthPartners Hematology and Oncology-Poulsbo Recruiting
Poulsbo, Washington, United States, 98370
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Valley Medical Center Recruiting
Renton, Washington, United States, 98055
Contact: Site Public Contact    425-228-3440    research@valleymed.org   
Principal Investigator: John A. Ellerton         
Pacific Gynecology Specialists Recruiting
Seattle, Washington, United States, 98104
Contact: Site Public Contact    206-215-3086    PCRC-NCORP@Swedish.org   
Principal Investigator: Alison K. Conlin         
Swedish Medical Center-Ballard Campus Recruiting
Seattle, Washington, United States, 98107
Contact: Site Public Contact    206-215-3086    PCRC-NCORP@Swedish.org   
Principal Investigator: Alison K. Conlin         
Swedish Medical Center-First Hill Recruiting
Seattle, Washington, United States, 98122-4307
Contact: Site Public Contact    206-215-3086    PCRC-NCORP@Swedish.org   
Principal Investigator: Alison K. Conlin         
Swedish Medical Center-Cherry Hill Recruiting
Seattle, Washington, United States, 98122-5711
Contact: Site Public Contact    206-215-3086    PCRC-NCORP@Swedish.org   
Principal Investigator: Alison K. Conlin         
PeaceHealth United General Medical Center Recruiting
Sedro-Woolley, Washington, United States, 98284
Contact: Site Public Contact    360-788-8240      
Principal Investigator: Alison K. Conlin         
Providence Regional Cancer System-Shelton Recruiting
Shelton, Washington, United States, 98584
Contact: Site Public Contact    360-412-8958    deidre.dillon@providence.org   
Principal Investigator: Alison K. Conlin         
Franciscan Research Center-Northwest Medical Plaza Recruiting
Tacoma, Washington, United States, 98405
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
PeaceHealth Southwest Medical Center Recruiting
Vancouver, Washington, United States, 98664
Contact: Site Public Contact    360-514-3940    kmakin-bond@peacehealth.org   
Principal Investigator: Alison K. Conlin         
Providence Saint Mary Regional Cancer Center Recruiting
Walla Walla, Washington, United States, 99362
Contact: Site Public Contact    509-897-5993    Cheryl.Dodd@providence.org   
Principal Investigator: Alison K. Conlin         
Providence Regional Cancer System-Yelm Recruiting
Yelm, Washington, United States, 98597
Contact: Site Public Contact    360-412-8958    deidre.dillon@providence.org   
Principal Investigator: Alison K. Conlin         
United States, Wisconsin
Mayo Clinic Health System-Eau Claire Clinic Recruiting
Eau Claire, Wisconsin, United States, 54701
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Lance C. Pagliaro         
ProHealth D N Greenwald Center Recruiting
Mukwonago, Wisconsin, United States, 53149
Contact: Site Public Contact       research.institute@phci.org   
Principal Investigator: Timothy R. Wassenaar         
Cancer Center of Western Wisconsin Recruiting
New Richmond, Wisconsin, United States, 54017
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Daniel M. Anderson         
ProHealth Oconomowoc Memorial Hospital Recruiting
Oconomowoc, Wisconsin, United States, 53066
Contact: Site Public Contact    262-928-7878      
Principal Investigator: Timothy R. Wassenaar         
ProHealth Waukesha Memorial Hospital Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Site Public Contact    262-928-7632      
Principal Investigator: Timothy R. Wassenaar         
UW Cancer Center at ProHealth Care Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Site Public Contact    262-928-5539    Chanda.miller@phci.org   
Principal Investigator: Timothy R. Wassenaar         
United States, Wyoming
Billings Clinic-Cody Recruiting
Cody, Wyoming, United States, 82414
Contact: Site Public Contact    800-996-2663    research@billingsclinic.org   
Principal Investigator: John M. Schallenkamp         
Welch Cancer Center Recruiting
Sheridan, Wyoming, United States, 82801
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Andrea B Apolo Alliance for Clinical Trials in Oncology

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03866382     History of Changes
Other Study ID Numbers: NCI-2019-01266
NCI-2019-01266 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
A031702 ( Other Identifier: Alliance for Clinical Trials in Oncology )
A031702 ( Other Identifier: CTEP )
U10CA180821 ( U.S. NIH Grant/Contract )
First Posted: March 7, 2019    Key Record Dates
Last Update Posted: October 18, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
URL: https://grants.nih.gov/policy/sharing.htm

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Urinary Bladder Neoplasms
Thyroid Neoplasms
Penile Neoplasms
Leydig Cell Tumor
Sertoli Cell Tumor
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Neoplasms, Squamous Cell
Urologic Neoplasms
Kidney Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neoplasms, Ductal, Lobular, and Medullary
Endocrine Gland Neoplasms
Head and Neck Neoplasms
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Sertoli-Leydig Cell Tumor
Sex Cord-Gonadal Stromal Tumors
Neoplasms, Gonadal Tissue